# Pharmacokinetic Effect of Y-3 on Repaglinide，Warfarin and Omeprazole in Healthy Participants

> **NCT07068841** · PHASE1 · COMPLETED · sponsor: **Neurodawn Pharmaceutical Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Pharmacokinetic Profiles
- Y-3 for Injection
- Drug-drug Interaction
- Repaglinide Tablets
- Warfarin Sodium Tablets
- Omeprazole Enteric-coated Capsules
- Safty

## Interventions

- **DRUG:** sequentially single use of repaglinide, warfarin and omeprazole or combined with Y-3

## Key facts

- **NCT ID:** NCT07068841
- **Lead sponsor:** Neurodawn Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-05-18
- **Primary completion:** 2025-06-29
- **Final completion:** 2025-06-29
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07068841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07068841, "Pharmacokinetic Effect of Y-3 on Repaglinide，Warfarin and Omeprazole in Healthy Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07068841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*